Icon (ICLR) plc announced the expansion of its early phase capabilities with the opening of a new, state-of-the-art Clinical Research Unit in San Antonio, Texas, as well as new satellite outpatient clinics in Houston, Texas and Lawrence, Kansas. These new, purpose-built clinics will significantly expand ICON’s capacity to conduct first-in-human, healthy participant, and patient cohort studies. “We’ve designed the clinic to improve the experience of study participants, while scaling our capacity and maintaining our high-quality standards,” said Dr. Ute Berger, ICON’s Chief Medical Officer and President, Development Solutions. “By fully integrating our clinical, laboratory, and pharmacy operations under one roof, we can largely eliminate logistical delays. This translates directly into faster dosing, real-time adaptability, and accelerated delivery of high-quality data for our sponsors. We are proud to invest in the San Antonio life sciences community and to contribute to its continued growth as a hub for innovation.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICLR:
- Icon price target raised to $125 from $105 at Leerink
- ICON plc Delays Annual 20-F Amid Restatement
- Icon says Audit Committee completes investigation into accounting practices
- ICON to Restate 2023–2025 Results After Audit Flags Revenue Recognition Issues
- ICON plc options imply 12.4% move in share price post-earnings
